Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.

Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infect...

Descripción completa

Detalles Bibliográficos
Autores: Alonso Padilla, Julio, Abril, Marcelo, Alarcón de Noya, Belkisyolé, Almeida, Igor Correia de, Angheben, Andrea, Araujo Jorge, Tania, Chatelain, Eric, Esteva, Mónica, Gascón i Brustenga, Joaquim, Grijalva, Mario J., Guhl, Felipe, Hasslocher-Moreno, Alejandro M., Lopez, Manuel C., Luquetti, Alejandro, Noya, Oscar, Pinazo, Maria-Jesus, Ramsey, Janine M., Ribeiro, Isabela, Ruiz, Andres M., Schijman, Alejandro G., Sosa-Estani, Sergio, Thomas, M.Carmen, Torrico, Faustino, Zrein, Maan, Picado de Puig, Albert
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/162636
Acceso en línea:https://hdl.handle.net/2445/162636
Access Level:acceso abierto
Palabra clave:Malaltia de Chagas
Parasitologia mèdica
Chagas' disease
Medical parasitology
id ES_71b787a1bf2d3f9967f3c1af2dd3e262
oai_identifier_str oai:diposit.ub.edu:2445/162636
network_acronym_str ES
network_name_str España
repository_id_str
spelling Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.Alonso Padilla, JulioAbril, MarceloAlarcón de Noya, BelkisyoléAlmeida, Igor Correia deAngheben, AndreaAraujo Jorge, TaniaChatelain, EricEsteva, MónicaGascón i Brustenga, JoaquimGrijalva, Mario J.Guhl, FelipeHasslocher-Moreno, Alejandro M.Lopez, Manuel C.Luquetti, AlejandroNoya, OscarPinazo, Maria-JesusRamsey, Janine M.Ribeiro, IsabelaRuiz, Andres M.Schijman, Alejandro G.Sosa-Estani, SergioThomas, M.CarmenTorrico, FaustinoZrein, MaanPicado de Puig, AlbertMalaltia de ChagasParasitologia mèdicaChagas' diseaseMedical parasitologySix to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change.PLoS2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/162636Articles publicats en revistes (ISGlobal)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: http://dx.doi.org/ 10.1371/journal.pntd.0008035PLoS Neglected Tropical Diseases , 2020 , vol. 14 , num.4 , p.e0008035http://dx.doi.org/ 10.1371/journal.pntd.0008035cc by (c) Alonso-Padilla et al., 2020http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1626362026-05-27T06:46:51Z
dc.title.none.fl_str_mv Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
title Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
spellingShingle Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
Alonso Padilla, Julio
Malaltia de Chagas
Parasitologia mèdica
Chagas' disease
Medical parasitology
title_short Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
title_full Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
title_fullStr Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
title_full_unstemmed Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
title_sort Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
dc.creator.none.fl_str_mv Alonso Padilla, Julio
Abril, Marcelo
Alarcón de Noya, Belkisyolé
Almeida, Igor Correia de
Angheben, Andrea
Araujo Jorge, Tania
Chatelain, Eric
Esteva, Mónica
Gascón i Brustenga, Joaquim
Grijalva, Mario J.
Guhl, Felipe
Hasslocher-Moreno, Alejandro M.
Lopez, Manuel C.
Luquetti, Alejandro
Noya, Oscar
Pinazo, Maria-Jesus
Ramsey, Janine M.
Ribeiro, Isabela
Ruiz, Andres M.
Schijman, Alejandro G.
Sosa-Estani, Sergio
Thomas, M.Carmen
Torrico, Faustino
Zrein, Maan
Picado de Puig, Albert
author Alonso Padilla, Julio
author_facet Alonso Padilla, Julio
Abril, Marcelo
Alarcón de Noya, Belkisyolé
Almeida, Igor Correia de
Angheben, Andrea
Araujo Jorge, Tania
Chatelain, Eric
Esteva, Mónica
Gascón i Brustenga, Joaquim
Grijalva, Mario J.
Guhl, Felipe
Hasslocher-Moreno, Alejandro M.
Lopez, Manuel C.
Luquetti, Alejandro
Noya, Oscar
Pinazo, Maria-Jesus
Ramsey, Janine M.
Ribeiro, Isabela
Ruiz, Andres M.
Schijman, Alejandro G.
Sosa-Estani, Sergio
Thomas, M.Carmen
Torrico, Faustino
Zrein, Maan
Picado de Puig, Albert
author_role author
author2 Abril, Marcelo
Alarcón de Noya, Belkisyolé
Almeida, Igor Correia de
Angheben, Andrea
Araujo Jorge, Tania
Chatelain, Eric
Esteva, Mónica
Gascón i Brustenga, Joaquim
Grijalva, Mario J.
Guhl, Felipe
Hasslocher-Moreno, Alejandro M.
Lopez, Manuel C.
Luquetti, Alejandro
Noya, Oscar
Pinazo, Maria-Jesus
Ramsey, Janine M.
Ribeiro, Isabela
Ruiz, Andres M.
Schijman, Alejandro G.
Sosa-Estani, Sergio
Thomas, M.Carmen
Torrico, Faustino
Zrein, Maan
Picado de Puig, Albert
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malaltia de Chagas
Parasitologia mèdica
Chagas' disease
Medical parasitology
topic Malaltia de Chagas
Parasitologia mèdica
Chagas' disease
Medical parasitology
description Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/162636
url https://hdl.handle.net/2445/162636
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/ 10.1371/journal.pntd.0008035
PLoS Neglected Tropical Diseases , 2020 , vol. 14 , num.4 , p.e0008035
http://dx.doi.org/ 10.1371/journal.pntd.0008035
dc.rights.none.fl_str_mv cc by (c) Alonso-Padilla et al., 2020
http://creativecommons.org/licenses/by/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Alonso-Padilla et al., 2020
http://creativecommons.org/licenses/by/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv PLoS
publisher.none.fl_str_mv PLoS
dc.source.none.fl_str_mv Articles publicats en revistes (ISGlobal)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410672544055296
score 15,301603

Similares en LA Referencia